# PROCEED + DETECT Year 9 supplement patient care costs

> **NIH NIH U01** · UNIVERSITY OF FLORIDA · 2023 · $135,000

## Abstract

Summary/Abstract
The Consortium for the Study of Chronic Pancreatitis, Diabetes, and Pancreatic Cancer
(CPDPC) was formed as a consequence of several NIH-sponsored workshops focused on
defining important research goals for improving care of patients with pancreatic diseases. The
goals of the CPDPC have been to investigate the clinically important inter-relationships between
pancreatitis, diabetes, and pancreatic cancer, focused on better understanding mechanisms,
pathophysiology, and natural history, on improving early diagnosis, discovering specific
biomarkers, and ultimately serving as a platform for exploratory and subsequent larger-scale
clinical trials. The CPDPC undertook these efforts through the establishment of several
prospective patient cohorts, coordinated and planned through the formation of several working
groups. These working groups (WGs) include the CP Adult WG, CP Pediatric WG, DM PDAC
WG, and the Type3C DM WG. The PROCEED cohort, organized by the CP Adult WG, will
ultimately include 1600 adult subjects, and is focused on patients with acute, acute relapsing,
and chronic pancreatitis. The INSPIRRE 2 cohort, organized by the CP Pediatric WG, will be
comprised of 860 children with acute relapsing and chronic pancreatitis. The DETECT cohort,
organized by the Type3C DM WG, is recruiting subjects with typical Type 2 diabetes mellitus as
well as patients with diabetes due to pancreatic cancer or chronic pancreatitis, to determine
mechanistic differences between these types of diabetes and leverage that information for
biomarker and therapeutic benefit. Each cohort will represent a large sample of deeply
phenotyped and characterized subjects, with comprehensive annotated biospecimen (biologic
samples, radiographic) collection, who are being followed over time. These cohorts, when fully
recruited and followed-up, provide a unique and powerful resource to address many
unanswered clinical questions and to address the goals of the CPDPC charter. The CPDPC is
organized to allow numerous ancillary studies to proceed in parallel to the main cohort
recruitment, and these ancillary studies now number more than 50. These ancillary studies
have helped inform the work of the CPDPC, and established a set of methods and protocols to
guide the consortium, as well as provide defined methods and definitions for future clinical
research in these diseases. The structure of the CPDPC provides an unparalleled opportunity
for internal and external collaboration to foster clinical studies and develop more effective
prediction, prevention, and treatment of complex pancreatic diseases.

## Key facts

- **NIH application ID:** 10887986
- **Project number:** 3U01DK108320-09S1
- **Recipient organization:** UNIVERSITY OF FLORIDA
- **Principal Investigator:** Kenneth Cusi
- **Activity code:** U01 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2023
- **Award amount:** $135,000
- **Award type:** 3
- **Project period:** 2015-09-28 → 2025-06-30

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10887986

## Citation

> US National Institutes of Health, RePORTER application 10887986, PROCEED + DETECT Year 9 supplement patient care costs (3U01DK108320-09S1). Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/grant/nih/10887986. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*